Celgene intends to file ozanimod for approval during the first quarter of 2019, a timeline for submission that generated mixed reactions among investors worried about the highly anticipated multiple sclerosis drug.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,